Jim Hoffman: Exploring Extracorporeal Strategies to Target NETs in Cardiovascular Disease
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared Apherese ForschungsInstitut – AFI’s post on LinkedIn, adding:
”Lp(a) does not act alone to help facilitate potentially life-threatening occlusive atheromas. Other factors, such as NETosis dysfunction and poor NET clearance, are likely at play, increasing the risk of CVD, heart failure, MI, and strokes.
Here are two other extracorporeal methods that target elevated extracellular chromatin/NETs that I believe should be trialed for potentially reversing diet and drug-refractory atherogenesis. They are simpler to perform and could be more efficacious than H.E.L.P. apheresis and other extracorporeal methods of lipid lowering.
A Novel Role for Lipoprotein(a) in Potentiating Neutrophil Extracellular Trap Formation.
More research linking NETosis dysfunction to atherosclerosis progression and atheroma development can be found
Quoting Apherese ForschungsInstitut – AFI’s post:
”Elevated Lipoprotein(a) is a major, genetically determined driver of cardiovascular risk, yet it remains largely untouched by traditional lifestyle changes and statins.
A recent review in the European Heart Journal titled ‘Lipoprotein(a)-lowering therapies: a promising future’ highlights the evolving landscape of treatment.
At the Apherese Forschungsinstitut, we closely follow these developments. Phase III trials of RNA-based therapies specifically targeting Lp(a) are currently underway. Until these new drugs reach the market and prove long-term outcomes, Lipoprotein Apheresis continues to be the life-saving ‘gold standard’ for patients with extreme Lp(a) elevation and progressive ASCVD.
In the current therapeutic landscape, Lipoprotein Apheresis remains the only established and highly effective method to significantly reduce Lp(a) levels and mitigate cardiovascular events in high-risk patients.”
Title: Lipoprotein(a)-lowering therapies: a promising future
Authors: Jingwen Zhang, Ann Marie Navar, Lale Tokgozoglu
Read the Full Article on Apherese ForschungsInstitut – AFI
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 27, 2026, 07:08Jeff Schaffnit: Global Voices in Hemophilia Care at the World Federation of Hemophilia World Congress
-
Apr 27, 2026, 06:44Andrew M. Evens: Award-Winning Research from the British Society for Haematology 66th Annual Meeting
-
Apr 27, 2026, 05:19Harshal Kale: Celebrating Hemophilia Partnerships on a Global Stage
-
Apr 26, 2026, 17:17Ajigbotosho Barakat: Leg Strength as a Key to Healthy Aging
-
Apr 26, 2026, 17:02Francisco Chacón-Lozsán: Limited Evidence Methylene Blue in Vasoplegic Shock
-
Apr 26, 2026, 16:57Gopal Patidar: Key Areas of Haemovigilance in ISBT Transfusion Today
-
Apr 26, 2026, 16:56Cathy Harrison: Oral Health in Older Adults Assessing the Impact of Ageing, Heart Failure, and Social Isolation
-
Apr 26, 2026, 15:08Andreas Ejlegård: Rebalancing Thrombosis and Hemostasis Through Mechanistic Innovation
-
Apr 26, 2026, 14:55Vanessa Simioni Faria: Precision Anticoagulation and Expanding Donor Frontiers